What were the main drivers of Ecolab's revenue growth in Q3 2024?

Ecolab's revenue growth in Q3 2024 was driven by a 4% increase in organic sales. This growth was observed across multiple segments, with notable contributions from Global Institutional & Specialty (up 7% organically) and Global Pest Elimination (up 8% organically). Strong value pricing and increased volumes were key factors contributing to this expansion.

How did the sale of the global surgical solutions business impact Ecolab's financial results?

The sale of the global surgical solutions business, which closed on August 1, 2024, resulted in a pre-tax gain of $365.3 million ($264.2 million after tax), or $0.92 per diluted share, recognized in the third quarter of 2024. This significantly boosted the company's net income and earnings per share for the period.

What is the 'One Ecolab' initiative and what are its expected impacts?

The 'One Ecolab' initiative, announced in July 2024, is designed to enhance the company's growth and margin expansion. As part of this, Ecolab commenced a restructuring plan to leverage digital technologies and consolidate functional work into global centers of excellence. The company anticipates total restructuring costs of $175 million and special charges of $50 million by the end of 2027. This initiative has already delivered $8 million in cumulative cost savings and is expected to generate annualized cost savings of $225 million by 2027.

How is Ecolab managing its debt and what is its liquidity position?

Ecolab continues to manage its debt effectively, with total debt decreasing to $7.6 billion as of September 30, 2024, from $8.2 billion at the end of 2023. The company's net debt to EBITDA ratio improved to 1.7 from 2.4. Ecolab maintains a strong liquidity position with $1,261.1 million in cash and cash equivalents and an undrawn $2.0 billion revolving credit facility, ensuring ample resources to fund operations, investments, and capital returns.

ECL 10-Q Quarterly Report Q3 FY2024 — Revenue, Net Income, EPS

Summary

Ecolab Inc. (ECL) reported a strong third quarter for fiscal year 2024, demonstrating robust sales growth and significant improvements in profitability. Net sales increased by 1% to $3,998.5 million, with organic sales growing by 4%, indicating healthy underlying business momentum across its key segments. The company experienced notable margin expansion, with reported gross margin improving to 43.4% from 41.1% in the prior year period, driven by effective value pricing and lower delivered product costs. Profitability saw a substantial uplift, with reported operating income surging by 85% year-over-year to $1,044.8 million. Net income attributable to Ecolab more than doubled to $736.5 million, and diluted EPS rose by 83% to $2.58. These gains were bolstered by the significant gain on the sale of the global surgical solutions business, but even on an adjusted basis, the company showed solid growth, with adjusted diluted EPS increasing by 19%. Ecolab continues to execute on its strategic initiatives, including the 'One Ecolab' program aimed at driving growth and margin expansion, and maintains a strong liquidity position with substantial cash reserves and available credit facilities.

Financial Highlights

53 data points

Beta

Revenue

$4.00B

0.4% Gross Margin

Net Income

$736.50M

0.2% Net Margin

EPS (Diluted)

$2.58

Total Assets

$22.10B

Cash & Equivalents

$1.26B

Free Cash Flow

$550.30M

Financial Statements

Beta

Revenue	$4.00B
Cost of Revenue	$2.26B
Gross Profit	$1.74B
SG&A Expenses	$1.02B
Operating Income	$1.04B
Interest Expense	$86.40M
Net Income	$736.50M
EPS (Basic)	$2.60
EPS (Diluted)	$2.58
Shares Outstanding (Basic)	283.60M
Shares Outstanding (Diluted)	286.00M

Key Highlights

1Net sales increased by 1% to $3,998.5 million in Q3 2024, with organic sales up 4%.
2Reported operating income increased by 85% to $1,044.8 million, and net income attributable to Ecolab rose 82% to $736.5 million.
3Diluted EPS saw a significant increase of 83% to $2.58.
4Gross margin improved to 43.4% from 41.1% in Q3 2023, reflecting strong pricing and lower costs.
5The company recognized a significant gain of $365.3 million from the sale of its global surgical solutions business.
6Ecolab is advancing its 'One Ecolab' initiative to enhance growth and margin expansion, with ongoing restructuring plans.
7The company maintained a strong liquidity position, with $1,261.1 million in cash and cash equivalents.

ECOLAB INC. Quarterly Report for Q3 Ended Sep 30, 2024

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions